COVID-19 | UPDATE

In the new reality of a global pandemic

Cancer doesn’t wait,
and neither do we.

As the world copes with COVID-19, our mission to conquer cancer with data continues.

Now more than ever, cancer patients, particularly those in late stages of the disease, need information to help guide their treatment. That’s why we’re working hard to enhance access to Guardant360 liquid biopsy testing by protecting patients from exposure to COVID-19, with services like mobile phlebotomy and virtual clinical consultations. We have also expanded our financial assistance program, taking into consideration the financial hardship of patients affected by the COVID-19 pandemic.

We have a unique responsibility to not only serve patients who need us now, but to impact patient care in the future. Therefore, our important research and development work continues. For our biopharma and research partners, we’ve implemented safeguards to ensure business continuity. Read the letter from Guardant Health’s COO, AmirAli Talasaz, to learn more.

The value that liquid biopsy can bring to cancer treatment is more essential than ever before.

Guardant Health remains steadfast in driving a blood-first paradigm for personalized oncology. The Guardant360 blood test is highly concordant with tissue biopsy testing, overcomes the challenges that this pandemic has either exacerbated or created around access to tumor tissue, and is an effective option for minimizing health risks for vulnerable groups, like patients with advanced cancer.

Helmy Eltoukhy I CEO I Guardant Health

“We believe it is our social responsibility to leverage our expertise during this crisis.”


Consistent with our belief that earlier cancer detection leads to better outcomes, we believe active surveillance of COVID-19 will benefit the health and safety of many essential businesses and communities. Given the significant testing needs for the foreseeable future, Guardant Health felt a social responsibility to leverage its expertise to contribute to this pressing need. We have developed a COVID-19 diagnostic test that has now received FDA emergency use authorization, and is being offered to our employees and select partner organizations. To learn more about accessing our Guardant-19 test, email: guardant19support@staging.guardanthealth.flywheelsites.com.

This page will continue to be updated as the situation evolves.